Australia's Regeneus sees best day in over 3 months on European patent grant

Cambium Bio

16/03/2021 01:00

** Shares of Regeneus  RGS.AX  jump as much as 14.3% to
A$0.120, eyeing their best day since Dec. 10, 2020
    ** The biotech co says European Patent Office has issued a
Notice of Intention to grant patent for its lead stem cell
technology platform Progenza™  urn:newsml:reuters.com:*:nASX7V8P9w
    ** Says patent gives protection for Progenza™ for the
treatment of pain in Europe through to 2032
    ** Stock hits its highest since March 5
    ** Stock has fallen 16% this year, as of last close
    
  

 (Reporting by Vasudha Kaukuntla in Bengaluru)
 ((Vasudha.Kaukuntla@thomsonreuters.com))